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A B S T R A C T
Objectives: To assess the prognostic implications of standardized reporting systems for coronary computed to-
mography angiography (CCTA) and coronary artery calcium scores (CACS) in patients with stable chest pain.
Background: The Coronary Artery Disease Reporting And Data System (CAD-RADS) and Coronary Artery
Calcium – Data and Reporting System (CAC-DRS) aim to improve communication of CACS and CCTA results, but
its influence on prognostication is unknown.
Methods: Images from 1769 patients who underwent CCTA as part of the Scottish Computed Tomography of the
HEART (SCOT-HEART) multi-center randomized controlled trial were assessed. CACS were classified as CAC-
DRS 0 to 3 based on Agatston scores. CCTA were classified as CAD-RADS 0 to 5 based on the most clinically
relevant finding per patient. The primary outcome was the five-year events of fatal and non-fatal myocardial
infarction.
Results: Patients had a mean age of 58 ± 10 years and 56% were male. CAC-DRS 0, 1, 2 and 3 occurred in 642
(36%), 510 (29%), 239 (14%) and 379 (21%) patients respectively. CAD-RADS 0, 1, 2, 3, 4A, 4B and 5 occurred
in 622 (35%), 327 (18%), 211 (12%), 165 (9%), 221 (12%), 42 (2%) and 181 (10%) patients respectively.
Patients classified as CAC-DRS 3 were at an increased risk of fatal or non-fatal myocardial infarction compared to
CAC-DRS 0 patients (hazard ratio (HR) 9.41; 95% confidence interval (CI) 3.24, 27.31; p < 0.001). Patients
with higher CAD-RADS categories were at an increased risk of fatal or non-fatal myocardial infarction, with
patients classified as CAD-RADS 4B at the highest risk compared to CAD-RADS 0 patients (HR 19.14; 95% CI
4.28, 85.53; p < 0.001).
Conclusion: Patients with higher CAC-DRS and CAD-RADS scores were at increased risk of subsequent fatal and
non-fatal myocardial infarction. This confirms that the classification provides additional prognostic dis-
crimination for future coronary heart disease events.
1. Introduction
Standardized reporting systems aim to improve the communication
of results to referring physicians and provide consistent reporting, in
order to aid quality assurance, education, research and peer-review.
Recently standardized reporting systems have been developed for
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coronary computed tomography angiography (CCTA) and coronary
artery calcium scoring (CACS).1,2 However, their clinical relevance for
prognostication is currently unknown.
The Coronary Artery Disease – Reporting And Data System (CAD-
RADS) classifies patients based on the highest grade of coronary artery
stenosis on CCTA, ranging from a score of zero for normal coronary
arteries to 5 for patients with at least one occluded coronary artery
(Table 1). The CAD-RADS system also includes additional modifiers for
the presence of vulnerable plaque (V), grafts (G) and stents (S). The
Coronary Artery Calcium – Data and Reporting System (CAC-DRS)
classifies patients based on either visual or quantitative assessment of
coronary artery calcification (Table 1). These scoring systems provide a
simple method to indicate the overall severity of disease to the referring
physician. Alongside disease severity, they also provide standardized
recommendations for subsequent management and investigation for
each category.1,2
The Scottish COmputed Tomography of the HEART (SCOT-HEART)
trial is a large prospective multi-center randomized controlled trial that
assessed the use of CCTA in patients with suspected angina due to
coronary heart disease.3 It showed that management based on CCTA
improves diagnostic certainty and reduced the rate of coronary heart
disease death and non-fatal myocardial infarction.4,5 This post-hoc
analysis of the SCOT-HEART trial aimed to assess the distribution of
CAD-RADS and CAC-DRS groups within the SCOT-HEART population
and to assess subsequent clinical outcomes.
2. Methods
2.1. Study design
The SCOT-HEART trial was a multicenter randomized controlled
trial investigating the use of CCTA in patients with suspected angina
due to coronary artery disease.3 The primary results of the SCOT-
HEART study have been published previously.4–6
2.2. Participants
In the SCOT-HEART study, 4146 patients attending cardiology out-
patient clinics with stable chest pain were randomized to standard care
or standard care plus CCTA. Of these participants, 2073 were rando-
mized to the intervention arm, and 1778 of these subsequently under-
went non-contrast electrocardiogram-gated computed tomography (CT)
for calcium scoring and CCTA as described previously.3,4 Cardiovas-
cular risk was calculated using the ASSIGN (Assessing cardiovascular
risk using SIGN guidelines) cardiovascular risk score as previously de-
scribed.7
2.3. CAC-DRS reporting system
In the SCOT-HEART trial, coronary artery calcium score was as-
sessed using the Agatston scoring system as described previously.3,8 In
the current study, each participant was assigned a CAC-DRS category2
based on their previously calculated Agatston score (Table 1).
2.4. CAD-RADS reporting system
As the classification of the CAD-RADS system differed from the as-
sessment of CCTA in the SCOT-HEART trial, all CCTA were reviewed
and recategorized according to CAD-RADS1 based on the most severe
stenosis (Table 1). The CAD-RADS V modifier was assigned to patients
with one or more plaques with two or more high-risk features, in-
cluding low attenuation plaque (< 30 Hounsfield Units), positive re-
modelling, spotty calcification or the “napkin ring” sign.1
2.5. Outcomes
Outcome information was obtained in March 2018 from the elec-
tronic Data Research and Innovation Service (eDRIS) of the National
Health Service (NHS) Scotland and confirmed by review of the patient
health records where required.5 The primary event for this sub-study
was the occurrence of coronary heart disease death or non-fatal myo-
cardial infarction.
2.6. Statistical analysis
Statistical analysis was performed using R version 3.5.0 (R
Foundation for Statistical Computing, Vienna, Austria). Quantitative
data are presented as mean and standard deviation or, if not normally
distributed, as median and interquartile range. Statistical significance
was assessed using Student t-test, Mann-Whitney U test, analysis of
variance, Chi-square test or Fisher's exact test as appropriate. Hazard
ratios (HR) and 95% confidence intervals (CI) are presented. Regression
analysis was performed to assess the effect of cardiovascular risk factors
on CAC-DRS and CAD-RADS scores. Variables which were statistically
significant on univariate analysis were included in multivariate ana-
lysis. Outcome data were analyzed using Cox proportional hazards re-
gression and presented graphically using cumulative incidence plots.
Due to small number of events, CAD-RADS categories 2 and 3, and 4
and 5 were combined. A statistically significant difference was defined
as a two-sided P value < 0.05.
3. Results
3.1. Patient demographics
Of the 1778 who underwent CT, there were 1769 CT images which
were of suitable image quality for analysis. Patients had a mean age of
58 ± 10 years and 56% were male (Table 2). The primary event of
Abbreviations list
CCTA coronary computed tomography angiography
CACS coronary artery calcium scoring
CAD-RADS Coronary Artery Disease – Reporting and Data
System
SCOT-HEART Scottish COmputed Tomography of the HEART
CAC-DRS Coronary Artery Calcium – Data and Reporting System
CT computed tomography
HR Hazard ratio
CI Confidence interval
Table 1
Summary of the CAC-DRS and CAD-RADS systems.1,2
CAC-DRS Agatston score
CAC-DRS 0 0
CAC-DRS 1 1–99
CAC-DRS 2 100–299
CAC-DRS 3 ≥300
CAD-RADS Degree of coronary stenosis
CAD-RADS 0 0% No plaque or stenosis
CAD-RADS 1 1–24% Minimal stenosis or plaque with
no stenosis
CAD-RADS 2 25–49% Mild stenosis
CAD-RADS 3 50–69% Moderate stenosis
CAD-RADS 4 A 70–99% Severe stenosis
CAD-RADS 4 B Left main stem >50% or 3
vessels ≥70%
Severe stenosis
CAD-RADS 5 100% Total occlusion
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coronary heart disease death or non-fatal myocardial infarction oc-
curred in 41 patients (2.3%) over a median follow-up of 4.7 years
(interquartile range [IQR], 4.0 to 5.7).
3.2. CAC-DRS
The median CAC score was 21 Agatston units [Interquartile range
(IQR) 0, 230] and the most frequent classifications were CAC-DRS 0
(36%) or 1 (29%) (Table 2). Patients with higher CAC-DRS classifica-
tions were more likely to be older male ex-smokers, and have typical
angina, a higher cardiovascular risk score, hypertension, diabetes, a
slightly lower total cholesterol, and a history of previous coronary ar-
tery or cerebrovascular disease (Table 2). In the multivariate model,
age, gender, smoking status, hypertension, history of previous coronary
heart disease, chest pain symptoms and cardiovascular risk score were
independent predictors of a higher CAC-DRS classification.
3.3. CAD-RADS
The most frequent CAD-RADS classification was 0 (normal coronary
arteries) occurring in 622 patients (35%, Table 3). Of the 642 patients
who were CAC-DRS 0, there were 112 (17%) who were categorised as
CAD-RADS 1 or above. Patients with higher CAD-RADS classification
were more likely to be older male non-smokers and have typical angina,
previous coronary heart disease, hypertension, diabetes and a higher
cardiovascular risk score. In the multivariate model, age, gender,
smoking status, chest pain symptoms, previous history of coronary
heart disease and cardiovascular risk score remained independent
predictors of a higher CAD-RADS classification. CADRADS V was
identified in 201 patients (11%) and was more frequent in patients with
a higher CAD-RADS score (Fig. 1; P < 0.001).
3.4. Medications and revascularisation
Prescription of preventative medications at 6 weeks and increased
Table 2
Demographic information for CAC-DRS subgroups.
All Participants CAC-DRS
0 1 2 3
Number 1769 642 (36) 509 (29) 239 (14) 379 (21)
Male 997 (56) 250 (39) 276 (54) 162 (68) 309 (82) *
Age 58 ± 10 53 ± 10 58 ± 9 61 ± 8 64 ± 7 *
Body mass index (kg/m2) 30 ± 6 30 ± 6 30 ± 6 29 ± 4 30 ± 5
Atrial fibrillation 34 (2) 12 (2) 8 (2) 4 (2) 10 (3)
Previous coronary heart disease 178 (10) 21 (3) 28 (6) 32 (13) 97 (26) *
Previous cerebrovascular disease 79 (4) 16 (2) 22 (4) 15 (6) 26 (7) *
Previous peripheral vascular disease 31 (2) 6 (1) 8 (2) 4 (2) 13 (3)
Smoking status Current smoker 330 (19) 127 (20) 99 (19) 55 (23) 49 (13) *
Ex-smoker 593 (34) 164 (26) 168 (33) 82 (34) 179 (47) *
Non-smoker 845 (48) 350 (55) 242 (48) 102 (43) 151 (40) *
Hypertension 608 (35) 153 (24) 175 (35) 85 (36) 195 (52) *
Diabetes 196 (11) 44 (7) 63 (12) 26 (11) 63 (17) *
Family history 765 (44) 279 (44) 230 (45) 104 (44) 152 (40)
Total cholesterol (mg/dL) 192 ± 73 196 ± 68 197 ± 72 189 ± 80 180 ± 74 *
Anginal symptoms Typical angina 654 (37) 148 (23) 185 (36) 96 (40) 225 (59) *
Atypical angina 432 (24) 178 (28) 117 (23) 70 (29) 67 (18) *
Non-anginal 683 (39) 316 (49) 207 (41) 73 (31) 87 (23) *
ASSIGN cardiovascular risk score 18 ± 11 12 ± 9 19 ± 11 22 ± 11 24 ± 11 *
Number and (percentage). *, p < 0.05.
Table 3
Demographic information for CAD-RADS subgroups.
CAD-RADS
0 1 2 3 4A 4B 5
Number 622 (35) 327 (18) 211 (12) 165 (9) 221 (12) 42 (2) 181 (10)
Male 252 (41) 173 (53) 126 (60) 105 (64) 160 (72) 32 (76) 149 (82)*
Age 53 ± 10 58 ± 8 60 ± 9 61 ± 8 61 ± 8 62 ± 8 62 ± 8 *
Body mass index (kg/m2) 30 ± 6 29 ± 5 29 ± 5 30 ± 5 29 ± 5 30 ± 5 30 ± 5
Atrial fibrillation 12 (2) 5 (2) 3 (1) 5 (3) 6 (3) 1 (2) 2 (1)
Previous coronary heart disease 18 (3) 16 (5) 34 (16) 23 (14) 30 (14) 10 (24) 47 (26)*
Previous cerebrovascular disease 15 (2) 15 (5) 13 (6) 11 (7) 17 (8) 1 (2) 7 (4)
Previous peripheral vascular disease 7 (1) 4 (1) 4 (2) 2 (1) 6 (3) 4 (10) 4 (2)
Smoking status Current smoker 112 (18) 58 (18) 47 (22) 27 (16) 45 (20) 8 (19) 33 (18) *
Ex-smoker 168 (27) 108 (33) 84 (40) 71 (43) 77 (35) 21 (50) 64 (35) *
Non-smoker 341 (55) 161 (49) 80 (38) 67 (41) 99 (45) 13 (31) 84 (46) *
Hypertension 155 (25) 111 (34) 69 (33) 74 (45) 104 (48) 16 (39) 79 (44)*
Diabetes 51 (8) 43 (13) 21 (10) 22 (13) 23 (11) 3 (7) 32 (18)*
Family history 273 (44) 148 (45) 92 (44) 66 (41) 101 (46) 21 (50) 64 (36)
Total cholesterol (mg/dL) 194 ± 67 196 ± 73 178 ± 83 192 ± 67 189 ± 75 195 ± 73 199 ± 77
Anginal symptoms Typical angina 152 (24) 87 (27) 66 (31) 61 (37) 131 (59) 24 (57) 133 (73) *
Atypical angina 163 (26) 89 (27) 59 (28) 42 (25) 46 (21) 9 (21) 24 (13) *
Non-anginal 307 (49) 151 (46) 86 (41) 62 (38) 44 (20) 9 (21) 24 (13)*
ASSIGN cardiovascular risk score 12.4 ± 8.7 18.7 ± 11.1 19.7 ± 10.8 20.5 ± 10.1 22.8 ± 10.7 21.2 ± 10.4 24.3 ± 11.6 *
Number and (percentage). *, p < 0.05.
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use of coronary revascularisation was associated with higher CAC-DRS
and CAD-RADS classification groups (p < 0.001 for both, Table 4,
Fig. 2). When comparing patients with a CAD-RADS classification of 4
or 5 to patients to those with CAD-RADS classification of 1, the odds
ratio for preventative medication use and coronary revascularisation
were 7.06 (95% CI, 4.42 to 11.70, p < 0.001) and 42.15 (95% CI,
20.98 to 100.48, p < 0.001) respectively.
3.5. Clinical outcomes
Patients in the highest CAC-DRS category were at an increased risk
of coronary heart disease death or non-fatal myocardial infarction
compared to those with CAC-DRS 0 (Table 4, Fig. 3). Similarly, patients
with a higher CAD-RADS classification were at an increased risk of
coronary heart disease death or non-fatal myocardial infarction
(Table 4, Fig. 4). Patients in CAD-RADS group 4B were at the highest
risk (Hazard ratio (HR) 19.14 (95% CI 4.28, 85.53), p= 0.0001), but
Fig. 1. Prevalence of CAD-RADS V classification in patients with different CAD-RADS categories.
Table 4
Medication use, revascularisation and subsequent outcomes in (A) CAC-DRS and (B) CAD-RADS subgroups.
CAC-DRS
CAC-DRS Preventative medications at 6 weeks Revascularisation CHD death or non-fatal myocardial infarctiona
N (%) Hazard ratioc
0 282 (44%) 7 (1%) 4 (1%) –
1 370 (73%) 45 (9%) 10 (2%) 3.15 (0.99, 10.06) p= 0.052
2 211 (88%) 53 (22%) 5 (2%) 3.34 (0.90, 12.43) p= 0.073
3 352 (93%) 145 (38%) 22 (6%) 9.41 (3.24, 27.31) p < 0.0001
CAD-RADS
CAD-RADS Preventative medications at 6 weeks Revascularisation CHD death or non-fatal myocardial infarctionb
N (%) Hazard ratioc
0 243 (39%) 0 3 (1%) –
1 236 (72%) 7 (2%) 7 (2%) 4.57 (1.18, 17.66) p= 0.03
2 170 (81%) 13 (6%) 4 (2%) 4.08 (0.91, 18.21) p= 0.07
3 145 (88%) 17 (10%) 7 (4%) 9.06 (2.34, 35.05) p= 0.001
4A 209 (95%) 94 (43%) 8 (4%) 7.66 (2.03, 28.85) p= 0.003
4B 41 (98%) 19 (45%) 4 (10%) 19.14 (4.28, 85.53) p= 0.0001
5 171 (94%) 100 (55%) 8 (4%) 9.22 (2.44, 34.74) p= 0.001
a Compared to patients with CAC-DRS 0.
b Compared to patients with CAD-RADS 0.
c Hazard ratio and 95% confidence interval. Number (percentage).
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there was overlap between CAD-RADS categories 3 to 5 (Supplementary
Fig. 1). We did not identify any difference in the rate of coronary heart
disease death or non-fatal myocardial infarction in patients with or
without the CAD-RADS V modifier (HR 1.59 (95% CI 0.70, 3.58),
p= 0.266; Fig. 5).
4. Discussion
CAC-DRS and CAD-RADS stratify patients across the range of cor-
onary artery disease, management and subsequent outcomes, with
some overlap between the groups in terms of 5-year outcomes. Patients
with low CAC-DRS or CAD-RADS scores have a very small, but not zero,
risk of subsequent cardiac events. In contrast, those in the highest CAC-
DRS and CAD-RADS categories were greater than 9 times more likely to
suffer coronary heart disease death or non-fatal myocardial infarction
than those with the lowest score.
CAC-DRS and CAD-RADS both follow a tradition of reporting and
data systems used to classify the probability of cancer based on imaging
findings.9–13 These systems aim to improve the communication of re-
sults to clinicians, to provide recommendations for further management
and to enhance research and audit. CAC-DRS and CAD-RADS mark a
departure from the use of these systems in cancer imaging and applies
the same structured reporting system to coronary artery disease. In
classifying disease based on the most severe stenosis, CAD-RADS is also
different to other CCTA scoring systems which quantified disease across
the entire coronary tree.14 In our study both CAC-DRS and CAD-RADS
successfully identify patients in the lowest risk groups, but there was
overlap in terms of management and outcomes in the other groups.
Multiple studies have shown the prognostic value of coronary artery
calcification and its additive value to traditional risk factors for pre-
dicting the presence of coronary artery disease or subsequent cardiac
events.15–20 In the PROMISE study, a cut-off of 400 Agatston units
identified patients with increased risk of cardiovascular death or
myocardial infarction with an adjusted hazard ratio of 1.92 (95% CI
0.84, 4.39).21 Similarly in the SCOT-HEART study, increased coronary
artery calcium score was associated with an increased risk of coronary
heart disease death or non-fatal myocardial infarction.22 The CAC-DRS
classification uses an upper limit of 300 Agatston units, potentially
underestimating the increased risk of even higher coronary artery cal-
cium score. Similar to previous studies, patients with no coronary artery
calcification were are at a lower, but not absent, risk of cardiac
events.21,23,24 Indeed, CCTA identified at-risk patients with plaque
disease but a calcium score of zero. Thus, coronary artery calcification
alone may lack sufficient sensitivity for the diagnosis of patients with
suspected angina due to coronary heart disease.
Patients classified as CAD-RADS 4B were at the highest risk of
subsequent events. These patients had left main stem stenosis> 50% or
3 vessel disease ≥70%. This is in keeping with other studies which
have shown that the presence of obstructive coronary artery disease is
associated with a poorer prognosis.25–27 In the CONFIRM registry
(COronary CT Angiography EvaluatioN For Clinical Outcomes: An In-
teRnational Multicenter) increasing CAD-RADS scores were associated
with an increased risk of death or myocardial infarction up to a hazard
ratio of 6.09 (95% CI 4.34 to 8.54) for patients with CAD-RADS 5.
However, CAD-RADS classifications based on a single stenosis may
merely be a surrogate marker of overall plaque burden. Indeed, it must
be remembered that most myocardial infarctions occur in segments
without previous obstructive coronary artery disease.28–30 Moreover,
Fig. 2. Use of preventative medication at 6 weeks and revascularisation in patients in different CAC-DRS and CAD-RADS categories.
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Fig. 3. Cumulative incidence curve of coronary heart disease (CHD) death or non-fatal myocardial infarction (MI) for patients with different CAC-DRS classifications.
Fig. 4. Cumulative incidence curve of coronary heart disease (CHD) death or non-fatal myocardial infarction (MI) with different CAD-RADS classifications.
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patients with borderline obstructive disease in our study (CAD-RADS 3,
50–69%) had event rates that were similar to those with critical or
occluded vessels. This is consistent with previous historical data de-
monstrating that 5-year myocardial infarction rates plateau above
coronary stenoses of> 50%.31 This finding may be because these CAD-
RADS 3 patients had a heavy burden of atherosclerotic plaque despite
the absence of obstructive disease, or because underlying character-
istics of their plaque or phenotype puts them at a greater risk of sub-
sequent coronary events. The factors contributing to myocardial in-
farction in patients without pre-existing obstructive coronary artery
disease warrants further investigation. In addition, this highlights that
there are subgroups of patients with non-obstructive coronary artery
disease who are at increased risk of cardiac events, and who may
benefit from more aggressive therapy.
The CAD-RADS V modifier was applied to 11% of patients in this
study, similar to the rate of high risk plaques identified in other stu-
dies.32 Interestingly, we did not identify an increased risk associated
with the CAD-RADS V modifier, despite other definitions of adverse
plaque being associated with an increased risk in the SCOT-HEART
population.22 In particular, the inclusion of spotty calcification in the
CAD-RADS V classification reduces the specificity of this modifier. The
definition of high risk plaque varies between studies.22,32,33 Using the
CAD-RADS definition of adverse plaque retrospectively did not identify
patients who subsequently experienced adverse events. However, an
alternative definition, using only the presence of positive remodelling
or low attenuation plaque, identified patients at increased risk of cor-
onary heart disease death or non-fatal myocardial infarction in the
SCOT-HEART population.22 An additional issue for the clinical use of
the CAD-RADS V classification is the considerable observer variability
in the classification of potentially “vulnerable” plaques.34 Inter-
observer reproducibility of the CAD-RADS system was found to be ex-
cellent, apart from the CAD-RADS V modifier which demonstrated only
fair agreement.34 Therefore, the CAD-RADS V modifier must be used
with caution and that an alternative definition should be considered.
Further standardization with quantitative assessment may provide a
more reliable definition.
The application of a system that originally was used to qualify a
cancer diagnosis to coronary artery disease does have some limita-
tions.35 First, the results of the CT scan are summarized with a single
classification based on the most severe disease in a single vessel. This
has the potential to underestimate the severity of multi-vessel disease,
especially when there is a large burden of non-obstructive disease. More
nuanced findings on CCTA also have the potential to be missed if only
the CAD-RADS classification is communicated to the referrer. In parti-
cular, the increased risk of subsequent fatal or non-fatal myocardial
infarction in a subset of CAD-RADS 3 patients (50–69% stenosis) must
be remembered and appropriately investigated and treated. The CAD-
RADS classification should therefore be considered in combination with
the overall scan report and its conclusions.
The main limitation of this study is that the CAD-RADS system was
applied retrospectively to the SCOT-HEART dataset. To date, the pro-
spective use of this classification system has not been assessed.
Similarly, no prospective data are available on management strategies
based on the identification of vulnerable plaque features. Nevertheless,
this study provides an interesting insight into the way in which CAC-
DRS and CAD-RADS classify a population with suspected angina due to
coronary artery disease and the potential outcomes in each group of
patients. In addition, the number of events that have occurred in this
low to intermediate risk population is small, particularly when split
between the subgroups. This precludes comparisons between every
Fig. 5. Kaplan-Meier curve of coronary heart disease (CHD) death or non-fatal myocardial infarction (MI) for patients with or without CAD-RADS V classification.
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subgroup and necessitated combining some of the CAD-RADS groups
for analysis.
This study shows that the CAC-DRS and CAD-RADS can stratify
patients undergoing non-invasive imaging, but that there is some
overlap between groups in terms of the 5 years outcomes, and that the
vulnerable plaque modifier does not add additional prognostic value in
this cohort. Similar to other reporting and data systems, CAC-DRS and
CAD-RADS will need to continue to evolve in the light of new
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